Cardiac effects of statins - Advancements and open questions

Cardiovascular Research

Volumn 66, Issue 3, 2005, Pages 427-429

  Laufs, Ulrich ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; ROSUVASTATIN; STATIN;

CHOLESTEROL BLOOD LEVEL; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REPERFUSION; STROKE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC;

EID: 19444369400     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.03.021     Document Type: Editorial

References (15)

1. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 2005 89 118
2. U. Laufs, J.K. Liao, and M. Böhm Lipid management with statins: the lower the better? Z Kardiol 93 2004 4 9
3. C.L. Wainwright Statins-is there no end to their usefulness? Cardiovasc Res 65 2005 296 298
4. A.M. Lefer, B. Campbell, Y.K. Shin, R. Scalia, R. Hayward, and D.J. Lefer Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts Circulation 100 1999 178 184
5. S. Wolfrum, A. Dendorfer, M. Schutt, B. Weidtmann, A. Heep, and K. Tempel Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway J Cardiovasc Pharmacol 44 2004 348 355
6. Y. Ikeda, L.H. Young, and A.M. Lefer Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats J Cardiovasc Pharmacol 41 2003 649 656
7. Y. Birnbaum, Y. Ye, S. Rosanio, S. Tavackoli, Z.Y. Hu, and E.R. Schwarz Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury Cardiovasc Res 65 2005 345 355
8. P. Di Napoli, A.A. Taccardi, A. Grilli, M.A. De Lutiis, A. Barsotti, and M. Felaco Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia/reperfusion injury in rat hearts Cardiovasc Res 66 2005 462 471
9. U. Landmesser, N. Engberding, F.H. Bahlmann, A. Schaefer, A. Wiencke, and A. Heineke Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase Circulation 110 2004 1933 1939
10. G.M. Bokoch, and BA. Diebold Current molecular models for NADPH oxidase regulation by Rac GTPase Blood 100 2002 2692 2696
11. M. Takemoto, K. Node, H. Nakagami, Y. Liao, M. Grimm, and Y. Takemoto Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J Clin Invest 108 2001 1429 1437
12. C. Maack, T. Kartes, H. Kilter, H.J. Schäfers, G. Nickenig, and M. Böhm Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment Circulation 108 2003 1567 1574
13. M. Böhm, A. Hjalmarson, J. Kjekshus, U. Laufs, J. McMurray, and D.J. van Veldhuisen Do we need a clinical trial in heart failure with statins? Z Kardiol 94 2005 223 230
14. K. Node, M. Fujita, M. Kitakaze, M. Hori, and JK. Liao Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 19 108 2003 839 843
15. U. Laufs, S. Wassmann, S. Schackmann, C. Heeschen, M. Böhm, and G. Nickenig Beneficial effects of statins in patients with non-ischemic heart failure Z Kardiol 93 2004 103 108